Table 4. Clinical efficacy comparison of EGFR-TKI in single EGFR mutation and concurrent gene alterations.

Best response	Single EGFR mutation (n=299)	Concurrent gene alterations (n=21)	P
CR	1(0.3%)	0(0.0%)	0.79
PR	186(62.2%)	10(47.6%)	0.18
SD	67(22.4%)	4(19.0%)	0.25
PD	46(15.4%)	7(33.3%)	0.03
ORR	62.5%	47.6%	0.17
DCR	84.9%	66.7%	0.03
Median PFS(month)	10.9	6.0	0.002
Median OS(month)	21.0	17.6	0.17